AMT

About AMT

Beijing Advanced Medical Technologies (AMT) is a medical device company established in 2011 by founder and chairman Liu Qing. The company focuses on developing and producing fully bioresorbable vascular stents using a proprietary 3D printing technology. It is headquartered in the Zhongguancun Biomedical Park in Beijing, China.

Founder Liu Qing has an extensive background in biomaterials and tissue engineering, holding a Ph.D. in Biomaterials from Twente University in the Netherlands and having conducted postdoctoral research at Rice University and Temple University in the US. Before establishing AMT, he founded 3D Biotek in New Jersey in 2007, which focused on tissue engineering products and absorbable vascular stents. His expertise in product development, GMP production, and FDA approval processes has guided AMT's direction.

AMT's core technology is its proprietary 3D Multi-axial Printing (3D-MAP) platform, an additive manufacturing process used to create bioresorbable stents. This method is presented as an alternative to traditional laser cutting, offering advantages such as increased manufacturing speed, reduced material waste, and lower costs. The company holds over 40 patents in the US, EU, and China for this technology. Its product pipeline includes devices for coronary, peripheral, and neurovascular interventions. Key products under development include the AMSorb® fully bioresorbable coronary stent and the PeriSorb® peripheral stent, both of which are in clinical trials in China. Additionally, the company has developed the Jetfall™, a CO2 angiography injector designed as a kidney-friendly alternative to traditional contrast agents, which has received clearance in the US, EU, and China.

The company's business model centers on the research, development, and commercialization of these advanced medical devices for the global market. AMT serves the pan-vascular intervention market, targeting cardiovascular, peripheral vascular, and neurovascular fields. In April 2026, AMT announced the completion of a Series D financing round of over 200 million RMB, intended to accelerate product development, global marketing, and strategic international expansion. The company has also expanded into non-vascular products like biodegradable biliary stents.